GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0072331113 | Thyroid | PTC | signal transduction by p53 class mediator | 92/5968 | 163/18723 | 7.29e-11 | 2.54e-09 | 92 |
GO:2001020112 | Thyroid | PTC | regulation of response to DNA damage stimulus | 113/5968 | 219/18723 | 9.37e-10 | 2.77e-08 | 113 |
GO:1901796113 | Thyroid | PTC | regulation of signal transduction by p53 class mediator | 58/5968 | 93/18723 | 1.38e-09 | 3.95e-08 | 58 |
GO:0007568111 | Thyroid | PTC | aging | 153/5968 | 339/18723 | 1.80e-07 | 3.34e-06 | 153 |
GO:000756917 | Thyroid | PTC | cell aging | 68/5968 | 132/18723 | 2.09e-06 | 2.84e-05 | 68 |
GO:0006898110 | Thyroid | PTC | receptor-mediated endocytosis | 112/5968 | 244/18723 | 2.87e-06 | 3.74e-05 | 112 |
GO:0072593110 | Thyroid | PTC | reactive oxygen species metabolic process | 108/5968 | 239/18723 | 1.02e-05 | 1.13e-04 | 108 |
GO:004277010 | Thyroid | PTC | signal transduction in response to DNA damage | 81/5968 | 172/18723 | 2.07e-05 | 2.08e-04 | 81 |
GO:1901798113 | Thyroid | PTC | positive regulation of signal transduction by p53 class mediator | 18/5968 | 25/18723 | 4.48e-05 | 4.05e-04 | 18 |
GO:20010229 | Thyroid | PTC | positive regulation of response to DNA damage stimulus | 53/5968 | 105/18723 | 5.51e-05 | 4.89e-04 | 53 |
GO:00903986 | Thyroid | PTC | cellular senescence | 47/5968 | 93/18723 | 1.37e-04 | 1.07e-03 | 47 |
GO:0030330112 | Thyroid | PTC | DNA damage response, signal transduction by p53 class mediator | 38/5968 | 72/18723 | 1.85e-04 | 1.40e-03 | 38 |
GO:004351617 | Thyroid | PTC | regulation of DNA damage response, signal transduction by p53 class mediator | 19/5968 | 34/18723 | 3.21e-03 | 1.57e-02 | 19 |
GO:0051346112 | Thyroid | PTC | negative regulation of hydrolase activity | 146/5968 | 379/18723 | 3.33e-03 | 1.62e-02 | 146 |
GO:00510518 | Thyroid | PTC | negative regulation of transport | 176/5968 | 470/18723 | 5.44e-03 | 2.49e-02 | 176 |
GO:190401913 | Thyroid | PTC | epithelial cell apoptotic process | 52/5968 | 121/18723 | 6.56e-03 | 2.86e-02 | 52 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:006219734 | Thyroid | ATC | cellular response to chemical stress | 188/6293 | 337/18723 | 3.16e-17 | 3.07e-15 | 188 |
GO:007233135 | Thyroid | ATC | signal transduction by p53 class mediator | 102/6293 | 163/18723 | 3.16e-14 | 1.75e-12 | 102 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLA2R1 | SNV | Missense_Mutation | | c.2424N>A | p.Phe808Leu | p.F808L | Q13018 | protein_coding | tolerated(0.81) | benign(0.003) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PLA2R1 | SNV | Missense_Mutation | novel | c.3556N>C | p.Asp1186His | p.D1186H | Q13018 | protein_coding | deleterious(0.03) | possibly_damaging(0.866) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLA2R1 | SNV | Missense_Mutation | novel | c.3794N>A | p.Ser1265Tyr | p.S1265Y | Q13018 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLA2R1 | SNV | Missense_Mutation | rs757654265 | c.1487N>T | p.Arg496Ile | p.R496I | Q13018 | protein_coding | tolerated(0.07) | benign(0.049) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLA2R1 | SNV | Missense_Mutation | rs762241008 | c.1826N>C | p.His609Pro | p.H609P | Q13018 | protein_coding | deleterious(0) | possibly_damaging(0.765) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
PLA2R1 | SNV | Missense_Mutation | | c.938N>G | p.Tyr313Cys | p.Y313C | Q13018 | protein_coding | deleterious(0.01) | possibly_damaging(0.907) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
PLA2R1 | SNV | Missense_Mutation | | c.2059N>G | p.Leu687Val | p.L687V | Q13018 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLA2R1 | SNV | Missense_Mutation | novel | c.3919N>C | p.Gly1307Arg | p.G1307R | Q13018 | protein_coding | tolerated(0.19) | benign(0.027) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PLA2R1 | SNV | Missense_Mutation | rs756774429 | c.1942N>A | p.Glu648Lys | p.E648K | Q13018 | protein_coding | tolerated(0.78) | benign(0) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PLA2R1 | SNV | Missense_Mutation | | c.2728C>G | p.Gln910Glu | p.Q910E | Q13018 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |